FDA OK's Amgen's Xgeva in hypercalcemia of malignancy
This article was originally published in Scrip
Executive Summary
Amgen gained another US indication for Xgeva (denosumab) on 8 December – this time as a treatment for hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy, a serious complication in patients with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis.